ArticleImmunity, inflammation and disease2025
Identification of Plasma Biomarkers for B7 Family Members Associated With Primary Sjögren's Syndrome.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo evaluate the plasma levels of B7 family members (B7-H1, B7-H2, B7-H3, B7-H4, B7-H5, and B7-H6) in primary Sjögren's syndrome (pSS) patients and investigate their potential associations with disease activity.
methodsThis study included 69 pSS patients and 59 healthy participants. The expression levels of six costimulatory molecules were measured using enzyme-linked immunosorbent assay (ELISA). Furthermore, we examined the potential correlations between the levels of soluble B7-H1 (sB7-H1), sB7-H2, sB7-H3, sB7-H4, sB7-H5, and sB7-H6 with clinical symptoms and laboratory parameters.
resultspSS patients showed significantly higher expression levels of sB7-H1, sB7-H2, and sB7-H5 compared to healthy controls (HCs) (p < 0.05). In contrast, sB7-H6 expression levels were significantly lower in pSS patients (p < 0.05). Correlation analysis revealed that sB7-H1 exhibited positive associations with RF, IgG, CRP, and ESR. sB7-H2 showed significant positive correlations with both IgG and ESR, while sB7-H3 exhibited a negative correlation with RF and a positive correlation with CRP. Additionally, sB7-H5 revealed significant positive correlations with RF, IgG, and ESR. In contrast, sB7-H6 demonstrated negative correlations with IgG, IgA, and ESR. ESSDAI-related analysis revealed a significant positive correlation between sB7-H1 and ESSDAI (p < 0.05), while sB7-H6 exhibited a significant negative correlation with ESSDAI (p < 0.05). sB7-H1 exhibited an increasing trend in patients with clinical symptoms such as xerostomia, xerophthalmia, decayed tooth, fatigue, arthralgia, and glandular swelling, as well as in those with high IgG levels and positivity for anti-SSB/La, anti-SSA/Ro60, and anti-SSA/Ro52. Conversely, sB7-H6 demonstrated a declining trend in these patient groups. The combined use of sB7-H1 and sB7-H6 demonstrates good effectiveness in diagnosing pSS and distinguishing disease activity levels.
conclusionOur results indicated that patients with pSS exhibited elevated expression of sB7-H1 and a reduction in sB7-H6. These changes were found to correlate with clinical symptoms and laboratory parameters, suggesting that sB7-H1 and sB7-H6 could potentially serve as biomarkers for pSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.